Yongqing Liu

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 5

Top Topics

Radical Prostatectomy

Cell Cycle Arrest

Top Venues

Fundamental & clinical pharmacology

Pharmaceutical biology

Development (Cambridge, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Shikang Wang, Leiqiang Han, Juan Li, Yongqing Liu, Shaoyong Wang
Inflammatory molecules facilitate the development of docetaxel-resistant prostate cancer cells in vitro and in vivo. Fundamental & clinical pharmacology 36 (5) (2022)
Juan Li, Rongmei Wang, Yongqing Liu, Yuqian Wu, Leiqiang Han, Lei Zheng, Zhengqiang Bao
FKA-A NPs enhances PTX-A NPs efficacy to suppress ovarian cancer via regulating Skp2/YAP pathway. Fundamental & clinical pharmacology (2022)
Shikang Wang, Qian Wang, Huijun Wang, Chengkun Qin, Xianping Cui, Lei Li, Yongqing Liu, Hong Chang
Induction of ROS and DNA damage-dependent senescence by icaritin contributes to its antitumor activity in hepatocellular carcinoma cells. Pharmaceutical biology 57 (1) (2020)
Shikang Wang, Huijun Wang, Baoyou Sun, Duanfeng Li, Jing Wu, Juan Li, Xiaona Tian, Chengkun Qin, Hong Chang, Yongqing Liu
Acetyl-11-keto-β-boswellic acid triggers premature senescence via induction of DNA damage accompanied by impairment of DNA repair genes in hepatocellular carcinoma cells in vitro and in vivo. Fundamental & clinical pharmacology 34 (1) (2019)
Le Zhang, Sandrine Ettou, Myda Khalid, Mary Taglienti, Dhawal Jain, Youngsook L Jung, Catherine Seager, Yongqing Liu, Kar-Hui Ng, Peter J Park, Jordan A Kreidberg
EED, a member of the polycomb group, is required for nephron differentiation and the maintenance of nephron progenitor cells. Development (Cambridge, England) 145 (14) (2018)